Treatment of 100 nM of this peptide in cancer cell lines (HeLa and BT-474) increases the levels of PML and SMRT, and inhibits intracellular PIN1 activity (Liu et al., 2010; Bedewy et al., 2017). The gene discussed is PIN1; the disease is cancer.